Lv11
50 积分 2026-04-14 加入
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review
25分钟前
已完结
Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort
43分钟前
已关闭
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study
51分钟前
已完结
Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice
1小时前
已完结
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
1小时前
已完结
Abstract CT301: SHR-A1811 ± adebrelimab as first-line (1L) treatment for advanced HER2-mutant NSCLC: A randomized phase 2 cohort from a phase 1b/2 study
1个月前
已完结
皖公网安备34019202002308
